Disclosures and Conflict of Interest Statement:
Dr. Kiss runs an externally funded laboratory (current grants are: American Heart Association [20CDA35310329], and NIH [R35GM137819-03, -03S1, -03S2, -03S3], plus two subcontracts to NIH Contract #: 75N93019C00045) that is actively designing and testing different candidate RNA therapeutics. All authors anticipate seeking appropriate intellectual property protection for promising candidates that emerge from the lab’s work. Both Dr. Kiss and Dr. Bejar are named inventors on a recently filed patent for a novel RNA therapy platform. Dr. Kiss also has patents planned for several additional RNA therapeutics and an inducible stable HUVEC cell line.
Further, Dr. Kiss owns a small number of shares of stock in several biotech companies that are independent of his lab’s research.
Finally, Dr. Kiss is often contacted by independent consulting firms and/or for-profit companies (and has served as a paid consultant and/or lecturer for more than one firm/company) seeking insights about different research methodologies and/or topics that are broadly related to his lab’s research. Dr. Kiss has also been (and continues to be) a consultant to the RNA Core at the Houston Methodist Research Institute.